Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials.

Eric P BorrelliConor G McGladrigan

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

This analysis helps to highlight the importance of conducting postmarketing pharmacovigilance studies to better understand the potential adverse reactions of these medications.

Keyphrases

multiple myeloma
randomized controlled trial
adverse drug
drug administration
drug induced
study protocol
risk assessment